News, features, and commentary about cancer-related issues ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...